Tibet Weixinkang Medicine Co Ltd (603676.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100002QQ3

Price
8.28 CNY
Market cap
3.60 bn CNY
P/E (2025)
15.47
P/S (2025)
3.17
Dividend yield
3.95 %
Net margin
20.50 %
Return on equity (ROE)
15.77 %
Return on assets (ROA)
12.47 %

Tibet Weixinkang Medicine Co Ltd financials

Fiscal year20242025
Revenue1.30 bn CNY1.14 bn CNY
Gross profit695.98 m CNY697.94 m CNY
Operating income280.86 m CNY259.34 m CNY
EBIT276.83 m CNY283.83 m CNY
Net income246.17 m CNY232.85 m CNY
Diluted EPS – continuing operations0.57 CNY0.54 CNY

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Tibet Weixinkang Medicine Co Ltd

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium aspartate, carbohydrate and electrolyte, pentoxifylline, piracetam, and dopamine hydrochloride injections; and acetylcysteine solution for inhalation. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2002 and is based in Lhasa, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.